查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
2096647

尿道感染檢測市場－2026-2032年全球市場預測

Urinary Tract Infection Testing Market - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 199 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2032 年，尿道感染檢測市場將成長至 16.5 億美元，複合年成長率為 4.65%。

主要市場統計數據
基準年 2025 12億美元
預計年份：2026年 12.6億美元
預測年份 2032 16.5億美元
複合年成長率 (%) 4.65%

隨著醫療保健系統努力改善抗生素使用、減少復發性行為感染並加快基層醫療、急診醫學、泌尿系統、產科、小兒科和長期護理等各科室的治療決策，尿道感染尿道感染（ UTI）檢測正成為現代診斷的重要組成部分。泌尿道感染仍然是全球最常見的細菌感染疾病之一，對女性、老年人、孕婦、導尿管使用者、糖尿病患者和免疫力缺乏低下者造成沉重的臨床負擔。雖然傳統的尿液檢查和培養仍然是診斷的基礎，但快速試紙檢測、自動化尿沉渣分析、基於質譜的病原體鑑定、分子檢測、抗生素敏感性試驗和即時檢測（PoC）平台正在改變臨床醫生確診感染疾病和識別抗藥性菌株的方式。經營團隊重點正從單純的檢測轉向具有臨床指導意義的尿道感染檢測，以支持更快的診斷、更有針對性的抗生素使用、減少併發症和改善患者照護流程。

尿道感染檢測領域的變革性變化。

尿道感染(UTI) 檢測領域正經歷重大變革，從集中式、依賴培養的工作流程轉向更快、更整合、以病人為中心的診斷模式。隨著人們對抗生素抗藥性的日益關注，能夠區分細菌感染和定植、早期識別病原體並根據藥敏資訊指導治療的檢測方法的需求不斷成長。臨床檢查室正在採用自動化技術來提高處理能力、規範結果解讀並縮短報告時間。同時，醫療機構正在門診、急診、長期照護和遠端醫療場所推廣即時檢測 (POC)尿液檢查。數位化連結也在改變報告工作流程，將診斷結果與電子健康記錄、臨床決策支援系統和抗生素使用方案整合起來。同時，針對分析有效性、臨床表現、品管和檢測結果負責任解讀的監管要求也在不斷加強，尤其是在分子層面的尿道感染診斷領域。這些變化正在加強尿道感染(UTI) 檢測作為策略診斷領域的地位，該領域與精準醫療、感染控制和基於價值的醫療相結合。

人工智慧對尿道感染檢測的累積影響

人工智慧 (AI) 透過提高基於影像的尿沉渣分析的準確性、實現顯微鏡檢查自動化、輔助解讀培養結果以及幫助臨床醫生識別有併發症或復發性尿道感染感染風險的患者，對尿道感染感染 ( 尿道感染)檢測產生了日益顯著的影響。 AI 平台可以幫助檢查室檢體陰性樣本、標記異常觀察、減少人工工作量，並提高高通量偵測環境下的偵測一致性。在臨床實踐中，機器學習模型可以透過整合尿液檢查參數、患者人口統計資料、既往微生物學檢測結果、合併症、導尿管使用情況、懷孕狀態和處方史等信息，提高診斷信心並輔助選擇抗生素。將 AI 整合到檢驗的工作流程中，而不是將其作為獨立的決策工具，預計能發揮最大的作用。資料品質、人群代表性、網路安全、可解釋性、可審計性和臨床管治仍然是安全實施的關鍵要素。如果負責任地實施，人工智慧可以幫助減少不必要的抗生素處方，縮短標靶治療的時間，並加強對泌尿道病原體抗藥性模式的監測。

區域層面關於全球尿道感染檢測普及度的重要見解。

在亞太地區，中國、印度、日本、韓國和澳洲等國家由於城市人口眾多、診斷基礎設施不斷完善、門診病人巨大、人口老齡化以及對抗生素抗藥性監測日益重視，正在推動尿道感染（UTI）檢測的需求成長。在該地區，隨著公立和私立醫療機構致力於改善醫療服務可近性並提高檢查室效率，自動化尿液檢查、基於培養的診斷方法和快速檢測的使用正在不斷擴展。在歐洲，完善的微生物學標準、以合理使用抗生素為重點的處方指南、體外診斷的監管框架以及對初級和二級醫療機構中尿液檢查、培養和藥敏試驗循證應用的高度重視，都促進了這一需求的成長。北美地區的特點是臨床實驗室網路成熟、電子健康記錄廣泛應用、抗生素使用要求以及對分子和即時檢測（POC​​）尿路感染診斷（尤其是複發性、導尿管相關和併發症感染疾病）日益成長的興趣。在拉丁美洲，透過醫院檢查室、公共衛生計畫和私人診斷網路，診斷服務的可近性正在不斷擴大，但報銷制度、檢查室能力和農村地區可近性方面的差異仍然影響著檢測途徑。在非洲，儘管泌尿道感染診斷的需求遠未得到滿足，但加強檢測系統的努力也在不斷推進，經濟實惠的即時檢測、抗生素抗藥性監測和檢體轉診系統對於改善患者預後變得越來越重要。在中東，隨著醫院現代化、對數位醫療的投資以及先進診斷技術的應用，尿路感染檢測的需求與糖尿病的流行、導尿管相關感染疾病、三級醫療服務的擴展以及感染預防的優先事項密切相關。

針對特定族群的尿路感染檢查重點的關鍵見解

在北約成員國（其中許多與醫療衛生已開發經濟體重疊），人們越來越重視建立具有韌性的醫療衛生基礎設施、加強軍民感染疾病監測以及建立標準化的診斷系統，這進一步凸顯了在日常診療、部署和緊急醫療環境中進行可靠的尿道感染）檢測的重要性。七國集團（G7）國家普遍擁有成熟的保險報銷體系、完善的微生物學基礎設施、較高的數位醫療普及率，並在尿道感染感染診斷中積極採用自動化、品管系統和臨床決策支援系統。金磚國家（BRICS）的診斷體系多元且具影響力，擁有大規模的患者群體、日益沉重的慢性病負擔、不斷擴展的檢測網路，並且越來越重視能夠支持合理使用抗生素的經濟、快速的檢測方法。歐盟在合理使用抗生素、體外診斷醫療設備監管、檢查室品質保證和跨境抗藥性監測方面擁有領先的政策環境，因此對檢驗且具有臨床意義的尿道感染檢測有著強烈的需求。在東南亞國協，透過擴大基層醫療覆蓋範圍、升級醫院檢查室以及進行區域性抗擊抗生素抗藥性的努力，尿道感染檢測能力正在加強。然而，遍遠地區的診斷標準化和可近性仍存在差異。在海灣合作理事會（GCC）的醫療體系中，先進的醫院診斷、數位醫療的整合以及感染控制被列為優先事項，快速尿道感染檢測和基於藥敏試驗的治療在三級醫療、門診和慢性病管理中被認為至關重要。

主要國家尿道感染檢測趨勢

在中國，龐大的患者群體、都市區醫院的現代化以及全國對抗生素抗藥性的關注，推動了自動化臨床檢測和醫院分子診斷能力的快速發展。美國擁有高度發達的泌尿道感染（UTI）檢測體系，這得益於廣泛的門診檢測、醫院尿道感染檢測能力、抗生素使用規範、與電子健康記錄的整合以及分子診斷在複雜病例中日益廣泛的應用。在日本，檢查室自動化正在不斷進步，隨著人口老化，醫院和長期照護機構的臨床重點也轉向了複雜感染疾病的管理。在印度，尿道感染的高發生率以及培養和藥敏試驗可及性的顯著差異，使得經濟實惠的快速診斷、提高檢體品質以及加強抗生素使用教育顯得尤為重要。德國、英國、法國、義大利和西班牙展現了成熟的歐洲檢測環境，尿液檢查分析、尿液培養、藥敏試驗和處方指南與抗生素使用目標、檢查室認證和品質標準緊密相關。澳洲擁有完善的微生物學基礎設施，並制定了以合理使用抗生素為重點的指南，但尿液檢查途徑中，偏遠和農村地區的可及性仍然是一個關鍵考慮因素。韓國的特點是擁有先進的醫院檢查室、採用數位醫療，並專注於老年人和住院患者的複雜感染疾病管理。加拿大強調循證檢測、合理使用抗生素以及在各省醫療保健系統中實現公平的醫療服務獲取，尤其重視尿液培養的合理應用和抗藥性監測。俄羅斯擁有相當規模的醫院診斷能力，但其廣大的地域仍需要進行抗藥性監測，並提供標準化的檢測服務。巴西和墨西哥正在透過公共和私人檢查室網路加強診斷服務的可及性，但抗生素抗藥性、檢測可用性的差異以及對初級保健的高需求正在影響臨床實踐。

為尿道感染檢測行業的領導者提供的實用建議

產業領導者應優先考慮經臨床檢驗的尿道感染(UTI) 檢測解決方案，這些方案應支持合理使用抗生素，並加快獲得有效結果的速度。投資應集中於快速病原體檢測、反映藥敏資訊的流程、自動化尿液檢查、與實驗室資訊系統的整合，以及幫助臨床醫生避免過度治療無症狀性菌尿的決策支援。開發人員應針對不同的患者群體（包括老年人、孕婦、兒童患者、導尿患者、復發性尿道感染患者以及抗生素抗藥性高的地區）建立可靠的臨床證據。實驗室和醫療保健機構應整合基於臨床風險的檢測演算法，這些演算法應結合症狀評估、尿液檢查、培養確認和抗藥性分析。即時檢測 (PoC) 解決方案的設計應充分考慮易用性、品管、操作人員培訓和結果可追溯性，尤其是在基層醫療、急診醫學、長期護理和資源匱乏的環境中。此外，領導者應與醫療保健系統建立夥伴關係，以支援培訓、診斷管理、資料互通性和抗藥性監測，同時避免增加不適當檢測的使用。

理解實證尿道感染檢測的調查方法

本執行摘要採用基於檢驗的公共衛生、臨床、監管和科學資訊來源的二手研究途徑編寫。調查方法包括對尿道感染診斷、抗生素抗藥性、尿液檢查、尿液培養、快速檢測、分子診斷、抗生素敏感性檢測和即時檢測等方面的同行評審文獻進行回顧。此外，還考慮了來自權威衛生機構、感染控制機構、臨床實驗室醫學組織、抗生素合理使用框架以及體外診斷醫療設備監管文件的指導和監測觀點。本摘要整合了來自已記錄的醫療保健基礎設施趨勢、診斷可及性、臨床環境、疾病負擔以及監管因素的區域和國家特定見解。本分析有意排除市場規模和估計、市場佔有率和預測，而是專注於循證的行業趨勢、臨床需求、技術應用和戰略意義。所有見解均從診斷效用、病患結局、檢查室工作流程、抗生素合理使用和醫療保健系統準備等方面進行解讀。

關於尿道感染檢測未來發展的結論

尿道感染(UTI) 檢測正從簡單的常規尿液檢查發展成為一項具有戰略意義的診斷領域，有助於加快臨床決策、最佳化抗生素使用，並更好地管理複雜和復發性性行為感染。自動化、分子診斷、即時檢測平台、抗生素敏感性試驗和人工智慧正在提高尿道感染診斷的速度和一致性，但它們的價值在於臨床檢驗、負責任的解讀以及與診療路徑的整合。檢測能力、保險報銷、抗生素使用成熟度、監管合規性和醫療服務可及性等方面的區域差異將繼續影響技術部署的優先順序。那些將檢測創新與實證臨床指南、互通性、經濟性、品質保證和抗菌素抗藥性監測相結合的機構，將更有能力滿足不斷成長的診斷期望，並為疑似尿道感染患者提供更安全、更有針對性的治療。

目錄

第1章：序言

第2章：調查方法

  • 調查設計
  • 研究框架
  • 市場規模預測
  • 數據三角測量
  • 調查結果
  • 調查的前提
  • 研究限制

第3章執行摘要

  • 首席主管觀點
  • 市場規模和成長趨勢
  • 新的商機
  • 下一代經營模式
  • 產業藍圖

第4章 市場概覽

  • 產業生態系與價值鏈分析
  • 市場動態
  • 波特五力分析
  • PESTLE分析
  • 市場展望
  • 上市策略

第5章 市場洞察

  • 消費者洞察與終端用戶觀點
  • 消費者體驗基準
  • 機會映射
  • 分銷通路分析
  • 價格趨勢分析
  • 監理合規和標準框架
  • ESG與永續性分析
  • 中斷和風險情景
  • 投資報酬率和成本效益分析

第6章：人工智慧的累積影響，2026年

第7章：尿道感染檢測市場：依檢測類型分類

  • 自動化尿液檢查
    • 自動顯微鏡
    • 數位診斷影像
    • 流式細胞技術
  • 培養試驗
  • 分子檢測
    • 等溫擴增
    • 次世代定序
    • PCR檢測
  • 快速檢測
    • 油尺測試
    • 顯微鏡

第8章：尿道感染檢測市場：依技術分類

  • 自動化系統
    • 全自動
    • 半自動
  • 培養方法
  • 免疫測量
    • 化學冷光免疫檢測
    • ELISA
    • 橫向流動化驗
  • 分子診斷
    • 等溫法
    • 次世代定序
    • PCR

第9章：尿道感染檢測市場：依樣本類型分類

  • 導管置入
  • 中游清潔捕撈
  • 恥骨上穿刺

第10章：尿道感染檢測市場：依病原體類型分類

  • 細菌性尿道感染
  • 黴菌性尿道感染
  • 病毒性尿道感染

第11章：尿道感染檢測市場：依感染類型分類

  • 下尿道感染
  • 上尿道感染
  • 複雜性尿道感染
  • 單純性尿道感染

第12章：尿道感染檢測市場：依最終用戶分類

  • 診所
  • 診斷檢查室
  • 居家照護
  • 醫院

第13章：尿道感染檢測市場：按地區分類

  • 亞太地區
  • 歐洲
  • 北美洲
  • 拉丁美洲
  • 非洲
  • 中東

第14章：尿道感染檢測市場：依組別分類

  • NATO
  • G7
  • BRICS
  • EU
  • ASEAN
  • GCC

第15章：尿道感染檢測市場：依國家分類

  • 中國
  • 美國
  • 日本
  • 印度
  • 德國
  • 英國
  • 澳洲
  • 法國
  • 韓國
  • 義大利
  • 加拿大
  • 俄羅斯
  • 巴西
  • 墨西哥
  • 西班牙

第16章 競爭格局

  • 2025年市佔率分析
  • FPNV定位矩陣，2025
  • 市場集中度分析，2025年
    • 濃度比（CR）
    • 赫芬達爾-赫希曼指數 (HHI)
  • 近期趨勢及影響分析，2025 年
  • 2025年產品系列分析
  • 基準分析，2025 年

第17章：公司簡介

  • 77 Elektronika Kft.
  • Abbott Laboratories
  • Accelerate Diagnostics, Inc.
  • Acon Laboratories, Inc.
  • Arkray, Inc.
  • Becton, Dickinson and Company
  • Bio-Rad Laboratories, Inc.
  • Biocare Medical, LLC
  • bioMerieux SA
  • Cardinal Health, Inc.
  • Danaher Corporation
  • Dirui Industrial Co., Ltd.
  • EKF Diagnostics Holdings plc
  • F. Hoffmann-La Roche Ltd
  • Hologic, Inc.
  • Human Diagnostics Worldwide
  • Macherey-Nagel GmbH & Co. KG
  • Meridian Bioscience, Inc.
  • Mindray Medical International Limited
  • Nanosphere Health Sciences LLC
  • Nova Biomedical Corporation
  • QIAGEN NV
  • Randox Laboratories Ltd.
  • Sekisui Diagnostics, LLC
  • Siemens Healthineers AG
  • Sysmex Corporation
  • Thermo Fisher Scientific Inc.
  • Trivitron Healthcare
Product Code: MRR-7C50F27396DF

The Urinary Tract Infection Testing Market is projected to grow by USD 1.65 billion at a CAGR of 4.65% by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 1.20 billion
Estimated Year [2026] USD 1.26 billion
Forecast Year [2032] USD 1.65 billion
CAGR (%) 4.65%

Urinary tract infection testing is becoming a critical component of modern diagnostics as health systems work to improve antimicrobial stewardship, reduce recurrent infections, and accelerate treatment decisions across primary care, emergency medicine, urology, obstetrics, pediatrics, and long-term care. UTIs remain among the most common bacterial infections worldwide, with a high clinical burden among women, older adults, pregnant patients, catheterized individuals, people with diabetes, and immunocompromised populations. Traditional urinalysis and urine culture continue to provide foundational evidence for diagnosis, while rapid dipstick testing, automated urine sediment analysis, mass spectrometry-enabled organism identification, molecular assays, antimicrobial susceptibility testing, and point-of-care platforms are reshaping how clinicians confirm infection and identify resistance. The executive priority is shifting from simple detection to clinically actionable urinary tract infection testing that supports faster diagnosis, targeted antibiotic use, reduced complications, and improved patient pathways.

Transformative Shifts in the Urinary Tract Infection Testing Landscape

The urinary tract infection testing landscape is undergoing a decisive transition from centralized, culture-dependent workflows toward faster, integrated, and patient-centric diagnostic models. Rising concern over antimicrobial resistance is increasing demand for tests that can distinguish bacterial infection from colonization, identify pathogens earlier, and support susceptibility-informed therapy. Clinical laboratories are adopting automation to improve throughput, standardize interpretation, and reduce turnaround time, while healthcare providers are expanding point-of-care urine testing in outpatient, urgent care, long-term care, and remote-care settings. Digital connectivity is also transforming reporting workflows by linking diagnostic results with electronic health records, clinical decision support, and antimicrobial stewardship programs. At the same time, regulatory expectations for analytical validity, clinical performance, quality management, and responsible test interpretation are strengthening, particularly for molecular urinary tract infection diagnostics. These shifts are positioning UTI testing as a strategic diagnostic category aligned with precision medicine, infection control, and value-based care.

Cumulative Impact of Artificial Intelligence on UTI Testing

Artificial intelligence is increasingly influencing urinary tract infection testing by improving image-based urine sediment analysis, automating microscopic review, supporting culture interpretation, and helping clinicians identify patients at risk of complicated or recurrent UTI. AI-enabled platforms can assist laboratories in triaging negative samples, flagging abnormal findings, reducing manual workload, and improving consistency in high-volume testing environments. In clinical care, machine learning models can combine urinalysis parameters, patient demographics, prior microbiology results, comorbidities, catheter status, pregnancy status, and prescribing history to support diagnostic confidence and antibiotic selection. The most meaningful impact is expected where AI is embedded into validated workflows rather than used as a standalone decision-maker. Data quality, demographic representativeness, cybersecurity, explainability, auditability, and clinical governance remain essential to safe adoption. When implemented responsibly, AI can help reduce unnecessary antibiotic prescribing, shorten time to targeted therapy, and enhance surveillance of resistance patterns in urinary tract pathogens.

Key Regional Insights Across Global UTI Testing Adoption

In Asia-Pacific, urinary tract infection testing demand is shaped by dense urban populations, expanding diagnostic infrastructure, high outpatient volumes, aging demographics, and growing attention to antimicrobial resistance surveillance in countries such as China, India, Japan, South Korea, and Australia. The region is seeing broader use of automated urinalysis, culture confirmation, and rapid testing as public and private providers work to improve access and laboratory efficiency. Europe benefits from established microbiology standards, stewardship-focused prescribing guidance, in vitro diagnostic oversight, and a strong emphasis on evidence-based use of urinalysis, urine culture, and susceptibility testing across primary and secondary care. North America is characterized by mature clinical laboratory networks, strong uptake of electronic health records, antimicrobial stewardship requirements, and increasing interest in molecular and point-of-care UTI diagnostics, particularly for recurrent, catheter-associated, and complicated infections. Latin America is advancing diagnostic access through hospital-based laboratories, public health programs, and private diagnostic networks, although variability in reimbursement, laboratory capacity, and rural access continues to influence testing pathways. Africa presents a dual reality: major unmet need for accessible UTI diagnostics alongside growing laboratory strengthening initiatives, where affordable point-of-care testing, antimicrobial resistance monitoring, and specimen referral systems are increasingly important for improving patient outcomes. The Middle East is investing in hospital modernization, digital healthcare, and advanced diagnostics, with UTI testing needs closely tied to diabetes prevalence, catheter-associated infections, expanding tertiary care services, and infection prevention priorities.

Key Group Insights for UTI Testing Priorities

NATO member countries, many of which overlap with advanced healthcare economies, place growing emphasis on resilient healthcare infrastructure, military and civilian infection surveillance, and standardized diagnostic readiness, reinforcing the importance of reliable urinary tract infection testing across routine, deployed, and high-acuity care settings. G7 countries generally show mature reimbursement structures, well-developed microbiology infrastructure, high digital health penetration, and strong adoption of automation, quality systems, and clinical decision support for UTI diagnosis. BRICS countries represent diverse but high-impact diagnostic environments, combining large patient populations, rising chronic disease burden, expanding laboratory networks, and increasing emphasis on affordable rapid testing that can support antibiotic optimization. The European Union is a leading policy environment for antimicrobial stewardship, in vitro diagnostic regulation, laboratory quality assurance, and cross-border resistance monitoring, creating strong demand for validated, clinically interpretable UTI testing methods. ASEAN countries are strengthening urinary tract infection testing capacity through expanding primary care access, hospital laboratory modernization, and regional efforts to address antimicrobial resistance, although diagnostic standardization and rural access remain uneven. GCC health systems are prioritizing advanced hospital diagnostics, digital health integration, and infection control, making rapid UTI testing and susceptibility-informed treatment relevant to tertiary care, outpatient settings, and chronic disease management.

Key Country Insights in Urinary Tract Infection Testing

China is rapidly expanding automated laboratory diagnostics and hospital-based molecular capabilities, driven by large patient volumes, urban hospital modernization, and national concern around antimicrobial resistance. The United States has a highly developed urinary tract infection testing ecosystem supported by extensive outpatient testing, hospital microbiology capacity, antimicrobial stewardship programs, electronic health record integration, and growing use of molecular diagnostics for complex cases. Japan has advanced laboratory automation, an aging population, and strong clinical emphasis on managing complicated infections in hospital and long-term care settings. India faces high UTI burden and significant variation in access to culture and susceptibility testing, making affordable rapid diagnostics, specimen quality improvement, and stewardship education especially important. Germany, the United Kingdom, France, Italy, and Spain demonstrate mature European testing environments where urinalysis, urine culture, susceptibility testing, and prescribing guidance are closely linked to stewardship objectives, laboratory accreditation, and quality standards. Australia combines robust microbiology infrastructure with stewardship-focused guidelines, while remote and regional access remains an important consideration for urine testing pathways. South Korea is characterized by advanced hospital laboratories, digital healthcare adoption, and focused management of complicated infections among older and hospitalized patients. Canada emphasizes evidence-based testing, stewardship, and equitable access across provincial healthcare systems, with particular focus on appropriate urine culture use and resistance monitoring. Russia maintains substantial hospital-based diagnostic capacity, with ongoing need for resistance surveillance and standardized testing access across a large geography. Brazil and Mexico are strengthening diagnostic access through public and private laboratory networks, while antibiotic resistance, variability in testing availability, and high primary care demand shape clinical practice.

Actionable Recommendations for UTI Testing Industry Leaders

Industry leaders should prioritize clinically validated urinary tract infection testing solutions that shorten time to actionable results while supporting antimicrobial stewardship. Investments should focus on rapid pathogen detection, susceptibility-informed workflows, automated urinalysis, laboratory information system connectivity, and decision support that helps clinicians avoid overtreatment of asymptomatic bacteriuria. Developers should generate strong clinical evidence across diverse patient groups, including older adults, pregnant patients, pediatric patients, catheterized patients, recurrent UTI populations, and regions with high antimicrobial resistance. Laboratories and providers should integrate testing algorithms that combine symptom assessment, urinalysis, culture confirmation, and resistance profiling based on clinical risk. Point-of-care solutions should be designed for usability, quality control, operator training, and result traceability, especially in primary care, urgent care, long-term care, and low-resource settings. Leaders should also build partnerships with healthcare systems to support training, diagnostic stewardship, data interoperability, and resistance surveillance without increasing inappropriate test utilization.

Research Methodology for Evidence-Based UTI Testing Insights

This executive summary is developed using a secondary research approach grounded in verified public health, clinical, regulatory, and scientific sources. The methodology includes review of peer-reviewed literature on urinary tract infection diagnosis, antimicrobial resistance, urinalysis, urine culture, rapid testing, molecular diagnostics, antimicrobial susceptibility testing, and point-of-care testing. It also considers guidance and surveillance perspectives from recognized health authorities, infection control bodies, laboratory medicine organizations, antimicrobial stewardship frameworks, and in vitro diagnostic regulatory references. Regional and country insights are synthesized from documented healthcare infrastructure trends, diagnostic access patterns, clinical practice environments, disease burden considerations, and regulatory factors. The analysis deliberately excludes market sizing, market estimation, market share, and forecasting, focusing instead on evidence-backed industry dynamics, clinical needs, technology adoption, and strategic implications. All insights are interpreted through the lens of diagnostic utility, patient outcomes, laboratory workflow, antimicrobial stewardship, and healthcare system readiness.

Conclusion on the Future of Urinary Tract Infection Testing

Urinary tract infection testing is evolving from routine urine screening into a strategically important diagnostic field that supports faster clinical decisions, improved antibiotic stewardship, and better management of complicated and recurrent infections. Automation, molecular diagnostics, point-of-care platforms, antimicrobial susceptibility testing, and artificial intelligence are improving the speed and consistency of UTI diagnosis, but their value depends on clinical validation, responsible interpretation, and integration with care pathways. Regional differences in laboratory capacity, reimbursement, stewardship maturity, regulatory readiness, and healthcare access will continue to shape adoption priorities. Organizations that align testing innovation with evidence-based clinical guidelines, interoperability, affordability, quality assurance, and resistance surveillance will be best positioned to meet rising diagnostic expectations while supporting safer, more targeted treatment for patients with suspected urinary tract infection.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. New Revenue Opportunities
  • 3.5. Next-Generation Business Models
  • 3.6. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Market Dynamics
    • 4.3.1. Key Drivers
    • 4.3.2. Key Restraints
    • 4.3.3. Key Opportunities
    • 4.3.4. Key Challenges
  • 4.4. Porter's Five Forces Analysis
  • 4.5. PESTLE Analysis
  • 4.6. Market Outlook
    • 4.6.1. Near-Term Market Outlook (0-2 Years)
    • 4.6.2. Medium-Term Market Outlook (3-5 Years)
    • 4.6.3. Long-Term Market Outlook (5-10 Years)
  • 4.7. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of Artificial Intelligence 2026

7. Urinary Tract Infection Testing Market, by Test Type

  • 7.1. Introduction
  • 7.2. Automated Urinalysis
    • 7.2.1. Automated Microscopy
    • 7.2.2. Digital Imaging
    • 7.2.3. Flow Cytometry
  • 7.3. Culture Test
  • 7.4. Molecular Test
    • 7.4.1. Isothermal Amplification
    • 7.4.2. Next Generation Sequencing
    • 7.4.3. Pcr Assay
  • 7.5. Rapid Test
    • 7.5.1. Dipstick Test
    • 7.5.2. Microscopy

8. Urinary Tract Infection Testing Market, by Technology

  • 8.1. Introduction
  • 8.2. Automated Systems
    • 8.2.1. Fully Automated
    • 8.2.2. Semi Automated
  • 8.3. Culture Based
  • 8.4. Immunoassays
    • 8.4.1. Chemiluminescent Immunoassay
    • 8.4.2. Elisa
    • 8.4.3. Lateral Flow Assay
  • 8.5. Molecular Diagnostics
    • 8.5.1. Isothermal
    • 8.5.2. Next Generation Sequencing
    • 8.5.3. Pcr

9. Urinary Tract Infection Testing Market, by Sample Type

  • 9.1. Introduction
  • 9.2. Catheterized
  • 9.3. Midstream Clean Catch
  • 9.4. Suprapubic Aspiration

10. Urinary Tract Infection Testing Market, by Pathogen Type

  • 10.1. Introduction
  • 10.2. Bacterial UTI
  • 10.3. Fungal UTI
  • 10.4. Viral UTI

11. Urinary Tract Infection Testing Market, by Infection Type

  • 11.1. Introduction
  • 11.2. Lower Urinary Tract Infection
  • 11.3. Upper Urinary Tract Infection
  • 11.4. Complicated UTI
  • 11.5. Uncomplicated UTI

12. Urinary Tract Infection Testing Market, by End User

  • 12.1. Introduction
  • 12.2. Clinics
  • 12.3. Diagnostic Laboratories
  • 12.4. Home Care
  • 12.5. Hospitals

13. Urinary Tract Infection Testing Market, by Region

  • 13.1. Asia-Pacific
  • 13.2. Europe
  • 13.3. North America
  • 13.4. Latin America
  • 13.5. Africa
  • 13.6. Middle East

14. Urinary Tract Infection Testing Market, by Group

  • 14.1. NATO
  • 14.2. G7
  • 14.3. BRICS
  • 14.4. European Union
  • 14.5. ASEAN
  • 14.6. GCC

15. Urinary Tract Infection Testing Market, by Country

  • 15.1. China
  • 15.2. United States
  • 15.3. Japan
  • 15.4. India
  • 15.5. Germany
  • 15.6. United Kingdom
  • 15.7. Australia
  • 15.8. France
  • 15.9. South Korea
  • 15.10. Italy
  • 15.11. Canada
  • 15.12. Russia
  • 15.13. Brazil
  • 15.14. Mexico
  • 15.15. Spain

16. Competitive Landscape

  • 16.1. Market Share Analysis, 2025
  • 16.2. FPNV Positioning Matrix, 2025
  • 16.3. Market Concentration Analysis, 2025
    • 16.3.1. Concentration Ratio (CR)
    • 16.3.2. Herfindahl Hirschman Index (HHI)
  • 16.4. Recent Developments & Impact Analysis, 2025
  • 16.5. Product Portfolio Analysis, 2025
  • 16.6. Benchmarking Analysis, 2025

17. Company Profiles

  • 17.1. 77 Elektronika Kft.
  • 17.2. Abbott Laboratories
  • 17.3. Accelerate Diagnostics, Inc.
  • 17.4. Acon Laboratories, Inc.
  • 17.5. Arkray, Inc.
  • 17.6. Becton, Dickinson and Company
  • 17.7. Bio-Rad Laboratories, Inc.
  • 17.8. Biocare Medical, LLC
  • 17.9. bioMerieux SA
  • 17.10. Cardinal Health, Inc.
  • 17.11. Danaher Corporation
  • 17.12. Dirui Industrial Co., Ltd.
  • 17.13. EKF Diagnostics Holdings plc
  • 17.14. F. Hoffmann-La Roche Ltd
  • 17.15. Hologic, Inc.
  • 17.16. Human Diagnostics Worldwide
  • 17.17. Macherey-Nagel GmbH & Co. KG
  • 17.18. Meridian Bioscience, Inc.
  • 17.19. Mindray Medical International Limited
  • 17.20. Nanosphere Health Sciences LLC
  • 17.21. Nova Biomedical Corporation
  • 17.22. QIAGEN N.V.
  • 17.23. Randox Laboratories Ltd.
  • 17.24. Sekisui Diagnostics, LLC
  • 17.25. Siemens Healthineers AG
  • 17.26. Sysmex Corporation
  • 17.27. Thermo Fisher Scientific Inc.
  • 17.28. Trivitron Healthcare

LIST OF FIGURES

  • FIGURE 1. GLOBAL URINARY TRACT INFECTION TESTING MARKET, YEARS CONSIDERED FOR THE STUDY
  • FIGURE 2. GLOBAL URINARY TRACT INFECTION TESTING MARKET, RESEARCH DESIGN
  • FIGURE 3. GLOBAL URINARY TRACT INFECTION TESTING MARKET, RESEARCH FRAMEWORK
  • FIGURE 4. GLOBAL URINARY TRACT INFECTION TESTING MARKET, DATA TRIANGULATION
  • FIGURE 5. GLOBAL URINARY TRACT INFECTION TESTING MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 6. GLOBAL URINARY TRACT INFECTION TESTING MARKET SIZE, BY TEST TYPE, 2025 VS 2032 (%)
  • FIGURE 7. GLOBAL URINARY TRACT INFECTION TESTING MARKET SIZE, BY TEST TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL URINARY TRACT INFECTION TESTING MARKET SIZE, BY TECHNOLOGY, 2025 VS 2032 (%)
  • FIGURE 9. GLOBAL URINARY TRACT INFECTION TESTING MARKET SIZE, BY TECHNOLOGY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL URINARY TRACT INFECTION TESTING MARKET SIZE, BY SAMPLE TYPE, 2025 VS 2032 (%)
  • FIGURE 11. GLOBAL URINARY TRACT INFECTION TESTING MARKET SIZE, BY SAMPLE TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 12. GLOBAL URINARY TRACT INFECTION TESTING MARKET SIZE, BY PATHOGEN TYPE, 2025 VS 2032 (%)
  • FIGURE 13. GLOBAL URINARY TRACT INFECTION TESTING MARKET SIZE, BY PATHOGEN TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 14. GLOBAL URINARY TRACT INFECTION TESTING MARKET SIZE, BY INFECTION TYPE, 2025 VS 2032 (%)
  • FIGURE 15. GLOBAL URINARY TRACT INFECTION TESTING MARKET SIZE, BY INFECTION TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 16. GLOBAL URINARY TRACT INFECTION TESTING MARKET SIZE, BY END USER, 2025 VS 2032 (%)
  • FIGURE 17. GLOBAL URINARY TRACT INFECTION TESTING MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 18. GLOBAL URINARY TRACT INFECTION TESTING MARKET SIZE, BY REGION, 2025 VS 2032 (%)
  • FIGURE 19. GLOBAL URINARY TRACT INFECTION TESTING MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 20. GLOBAL URINARY TRACT INFECTION TESTING MARKET SIZE, BY GROUP, 2025 VS 2032 (%)
  • FIGURE 21. GLOBAL URINARY TRACT INFECTION TESTING MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 22. GLOBAL URINARY TRACT INFECTION TESTING MARKET SIZE, BY COUNTRY, 2025 VS 2032 (%)
  • FIGURE 23. GLOBAL URINARY TRACT INFECTION TESTING MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 24. GLOBAL URINARY TRACT INFECTION TESTING MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 25. GLOBAL URINARY TRACT INFECTION TESTING MARKET, FPNV POSITIONING MATRIX, BY KEY PLAYER, 2025

LIST OF TABLES

  • TABLE 1. GLOBAL URINARY TRACT INFECTION TESTING MARKET SEGMENTATION & COVERAGE
  • TABLE 2. GLOBAL URINARY TRACT INFECTION TESTING MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL URINARY TRACT INFECTION TESTING MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL AUTOMATED URINALYSIS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL AUTOMATED URINALYSIS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL AUTOMATED URINALYSIS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL AUTOMATED MICROSCOPY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL AUTOMATED MICROSCOPY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL AUTOMATED MICROSCOPY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL DIGITAL IMAGING MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL DIGITAL IMAGING MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL DIGITAL IMAGING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL FLOW CYTOMETRY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL FLOW CYTOMETRY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL FLOW CYTOMETRY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL CULTURE TEST MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL CULTURE TEST MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL CULTURE TEST MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL MOLECULAR TEST MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL MOLECULAR TEST MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL MOLECULAR TEST MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL ISOTHERMAL AMPLIFICATION MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL ISOTHERMAL AMPLIFICATION MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL ISOTHERMAL AMPLIFICATION MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL NEXT GENERATION SEQUENCING MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL NEXT GENERATION SEQUENCING MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL NEXT GENERATION SEQUENCING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL PCR ASSAY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL PCR ASSAY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL PCR ASSAY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL RAPID TEST MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL RAPID TEST MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL RAPID TEST MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL DIPSTICK TEST MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL DIPSTICK TEST MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL DIPSTICK TEST MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL MICROSCOPY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL MICROSCOPY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL MICROSCOPY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL URINARY TRACT INFECTION TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL AUTOMATED SYSTEMS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL AUTOMATED SYSTEMS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL AUTOMATED SYSTEMS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL FULLY AUTOMATED MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL FULLY AUTOMATED MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL FULLY AUTOMATED MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL SEMI AUTOMATED MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL SEMI AUTOMATED MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL SEMI AUTOMATED MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL CULTURE BASED MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL CULTURE BASED MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL CULTURE BASED MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL IMMUNOASSAYS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL IMMUNOASSAYS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL IMMUNOASSAYS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL CHEMILUMINESCENT IMMUNOASSAY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL CHEMILUMINESCENT IMMUNOASSAY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL CHEMILUMINESCENT IMMUNOASSAY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL ELISA MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL ELISA MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL ELISA MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL LATERAL FLOW ASSAY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL LATERAL FLOW ASSAY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL LATERAL FLOW ASSAY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL MOLECULAR DIAGNOSTICS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 66. GLOBAL MOLECULAR DIAGNOSTICS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 67. GLOBAL MOLECULAR DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 68. GLOBAL ISOTHERMAL MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 69. GLOBAL ISOTHERMAL MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 70. GLOBAL ISOTHERMAL MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 71. GLOBAL NEXT GENERATION SEQUENCING MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 72. GLOBAL NEXT GENERATION SEQUENCING MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 73. GLOBAL NEXT GENERATION SEQUENCING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 74. GLOBAL PCR MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 75. GLOBAL PCR MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 76. GLOBAL PCR MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 77. GLOBAL URINARY TRACT INFECTION TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 78. GLOBAL CATHETERIZED MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 79. GLOBAL CATHETERIZED MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 80. GLOBAL CATHETERIZED MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 81. GLOBAL MIDSTREAM CLEAN CATCH MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 82. GLOBAL MIDSTREAM CLEAN CATCH MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 83. GLOBAL MIDSTREAM CLEAN CATCH MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 84. GLOBAL SUPRAPUBIC ASPIRATION MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 85. GLOBAL SUPRAPUBIC ASPIRATION MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 86. GLOBAL SUPRAPUBIC ASPIRATION MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 87. GLOBAL URINARY TRACT INFECTION TESTING MARKET SIZE, BY PATHOGEN TYPE, 2018-2032 (USD MILLION)
  • TABLE 88. GLOBAL BACTERIAL UTI MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 89. GLOBAL BACTERIAL UTI MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 90. GLOBAL BACTERIAL UTI MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 91. GLOBAL FUNGAL UTI MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 92. GLOBAL FUNGAL UTI MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 93. GLOBAL FUNGAL UTI MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 94. GLOBAL VIRAL UTI MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 95. GLOBAL VIRAL UTI MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 96. GLOBAL VIRAL UTI MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 97. GLOBAL URINARY TRACT INFECTION TESTING MARKET SIZE, BY INFECTION TYPE, 2018-2032 (USD MILLION)
  • TABLE 98. GLOBAL LOWER URINARY TRACT INFECTION MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 99. GLOBAL LOWER URINARY TRACT INFECTION MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 100. GLOBAL LOWER URINARY TRACT INFECTION MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 101. GLOBAL UPPER URINARY TRACT INFECTION MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 102. GLOBAL UPPER URINARY TRACT INFECTION MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 103. GLOBAL UPPER URINARY TRACT INFECTION MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 104. GLOBAL COMPLICATED UTI MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 105. GLOBAL COMPLICATED UTI MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 106. GLOBAL COMPLICATED UTI MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 107. GLOBAL UNCOMPLICATED UTI MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 108. GLOBAL UNCOMPLICATED UTI MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 109. GLOBAL UNCOMPLICATED UTI MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 110. GLOBAL URINARY TRACT INFECTION TESTING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 111. GLOBAL CLINICS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 112. GLOBAL CLINICS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 113. GLOBAL CLINICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 114. GLOBAL DIAGNOSTIC LABORATORIES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 115. GLOBAL DIAGNOSTIC LABORATORIES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 116. GLOBAL DIAGNOSTIC LABORATORIES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 117. GLOBAL HOME CARE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 118. GLOBAL HOME CARE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 119. GLOBAL HOME CARE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 120. GLOBAL HOSPITALS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 121. GLOBAL HOSPITALS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 122. GLOBAL HOSPITALS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 123. GLOBAL URINARY TRACT INFECTION TESTING MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 124. ASIA-PACIFIC URINARY TRACT INFECTION TESTING MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 125. ASIA-PACIFIC URINARY TRACT INFECTION TESTING MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 126. ASIA-PACIFIC URINARY TRACT INFECTION TESTING MARKET SIZE, BY AUTOMATED URINALYSIS, 2018-2032 (USD MILLION)
  • TABLE 127. ASIA-PACIFIC URINARY TRACT INFECTION TESTING MARKET SIZE, BY MOLECULAR TEST, 2018-2032 (USD MILLION)
  • TABLE 128. ASIA-PACIFIC URINARY TRACT INFECTION TESTING MARKET SIZE, BY RAPID TEST, 2018-2032 (USD MILLION)
  • TABLE 129. ASIA-PACIFIC URINARY TRACT INFECTION TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 130. ASIA-PACIFIC URINARY TRACT INFECTION TESTING MARKET SIZE, BY AUTOMATED SYSTEMS, 2018-2032 (USD MILLION)
  • TABLE 131. ASIA-PACIFIC URINARY TRACT INFECTION TESTING MARKET SIZE, BY IMMUNOASSAYS, 2018-2032 (USD MILLION)
  • TABLE 132. ASIA-PACIFIC URINARY TRACT INFECTION TESTING MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 133. ASIA-PACIFIC URINARY TRACT INFECTION TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 134. ASIA-PACIFIC URINARY TRACT INFECTION TESTING MARKET SIZE, BY PATHOGEN TYPE, 2018-2032 (USD MILLION)
  • TABLE 135. ASIA-PACIFIC URINARY TRACT INFECTION TESTING MARKET SIZE, BY INFECTION TYPE, 2018-2032 (USD MILLION)
  • TABLE 136. ASIA-PACIFIC URINARY TRACT INFECTION TESTING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 137. EUROPE URINARY TRACT INFECTION TESTING MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 138. EUROPE URINARY TRACT INFECTION TESTING MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 139. EUROPE URINARY TRACT INFECTION TESTING MARKET SIZE, BY AUTOMATED URINALYSIS, 2018-2032 (USD MILLION)
  • TABLE 140. EUROPE URINARY TRACT INFECTION TESTING MARKET SIZE, BY MOLECULAR TEST, 2018-2032 (USD MILLION)
  • TABLE 141. EUROPE URINARY TRACT INFECTION TESTING MARKET SIZE, BY RAPID TEST, 2018-2032 (USD MILLION)
  • TABLE 142. EUROPE URINARY TRACT INFECTION TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 143. EUROPE URINARY TRACT INFECTION TESTING MARKET SIZE, BY AUTOMATED SYSTEMS, 2018-2032 (USD MILLION)
  • TABLE 144. EUROPE URINARY TRACT INFECTION TESTING MARKET SIZE, BY IMMUNOASSAYS, 2018-2032 (USD MILLION)
  • TABLE 145. EUROPE URINARY TRACT INFECTION TESTING MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 146. EUROPE URINARY TRACT INFECTION TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 147. EUROPE URINARY TRACT INFECTION TESTING MARKET SIZE, BY PATHOGEN TYPE, 2018-2032 (USD MILLION)
  • TABLE 148. EUROPE URINARY TRACT INFECTION TESTING MARKET SIZE, BY INFECTION TYPE, 2018-2032 (USD MILLION)
  • TABLE 149. EUROPE URINARY TRACT INFECTION TESTING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 150. NORTH AMERICA URINARY TRACT INFECTION TESTING MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 151. NORTH AMERICA URINARY TRACT INFECTION TESTING MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 152. NORTH AMERICA URINARY TRACT INFECTION TESTING MARKET SIZE, BY AUTOMATED URINALYSIS, 2018-2032 (USD MILLION)
  • TABLE 153. NORTH AMERICA URINARY TRACT INFECTION TESTING MARKET SIZE, BY MOLECULAR TEST, 2018-2032 (USD MILLION)
  • TABLE 154. NORTH AMERICA URINARY TRACT INFECTION TESTING MARKET SIZE, BY RAPID TEST, 2018-2032 (USD MILLION)
  • TABLE 155. NORTH AMERICA URINARY TRACT INFECTION TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 156. NORTH AMERICA URINARY TRACT INFECTION TESTING MARKET SIZE, BY AUTOMATED SYSTEMS, 2018-2032 (USD MILLION)
  • TABLE 157. NORTH AMERICA URINARY TRACT INFECTION TESTING MARKET SIZE, BY IMMUNOASSAYS, 2018-2032 (USD MILLION)
  • TABLE 158. NORTH AMERICA URINARY TRACT INFECTION TESTING MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 159. NORTH AMERICA URINARY TRACT INFECTION TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 160. NORTH AMERICA URINARY TRACT INFECTION TESTING MARKET SIZE, BY PATHOGEN TYPE, 2018-2032 (USD MILLION)
  • TABLE 161. NORTH AMERICA URINARY TRACT INFECTION TESTING MARKET SIZE, BY INFECTION TYPE, 2018-2032 (USD MILLION)
  • TABLE 162. NORTH AMERICA URINARY TRACT INFECTION TESTING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 163. LATIN AMERICA URINARY TRACT INFECTION TESTING MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 164. LATIN AMERICA URINARY TRACT INFECTION TESTING MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 165. LATIN AMERICA URINARY TRACT INFECTION TESTING MARKET SIZE, BY AUTOMATED URINALYSIS, 2018-2032 (USD MILLION)
  • TABLE 166. LATIN AMERICA URINARY TRACT INFECTION TESTING MARKET SIZE, BY MOLECULAR TEST, 2018-2032 (USD MILLION)
  • TABLE 167. LATIN AMERICA URINARY TRACT INFECTION TESTING MARKET SIZE, BY RAPID TEST, 2018-2032 (USD MILLION)
  • TABLE 168. LATIN AMERICA URINARY TRACT INFECTION TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 169. LATIN AMERICA URINARY TRACT INFECTION TESTING MARKET SIZE, BY AUTOMATED SYSTEMS, 2018-2032 (USD MILLION)
  • TABLE 170. LATIN AMERICA URINARY TRACT INFECTION TESTING MARKET SIZE, BY IMMUNOASSAYS, 2018-2032 (USD MILLION)
  • TABLE 171. LATIN AMERICA URINARY TRACT INFECTION TESTING MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 172. LATIN AMERICA URINARY TRACT INFECTION TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 173. LATIN AMERICA URINARY TRACT INFECTION TESTING MARKET SIZE, BY PATHOGEN TYPE, 2018-2032 (USD MILLION)
  • TABLE 174. LATIN AMERICA URINARY TRACT INFECTION TESTING MARKET SIZE, BY INFECTION TYPE, 2018-2032 (USD MILLION)
  • TABLE 175. LATIN AMERICA URINARY TRACT INFECTION TESTING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 176. AFRICA URINARY TRACT INFECTION TESTING MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 177. AFRICA URINARY TRACT INFECTION TESTING MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 178. AFRICA URINARY TRACT INFECTION TESTING MARKET SIZE, BY AUTOMATED URINALYSIS, 2018-2032 (USD MILLION)
  • TABLE 179. AFRICA URINARY TRACT INFECTION TESTING MARKET SIZE, BY MOLECULAR TEST, 2018-2032 (USD MILLION)
  • TABLE 180. AFRICA URINARY TRACT INFECTION TESTING MARKET SIZE, BY RAPID TEST, 2018-2032 (USD MILLION)
  • TABLE 181. AFRICA URINARY TRACT INFECTION TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 182. AFRICA URINARY TRACT INFECTION TESTING MARKET SIZE, BY AUTOMATED SYSTEMS, 2018-2032 (USD MILLION)
  • TABLE 183. AFRICA URINARY TRACT INFECTION TESTING MARKET SIZE, BY IMMUNOASSAYS, 2018-2032 (USD MILLION)
  • TABLE 184. AFRICA URINARY TRACT INFECTION TESTING MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 185. AFRICA URINARY TRACT INFECTION TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 186. AFRICA URINARY TRACT INFECTION TESTING MARKET SIZE, BY PATHOGEN TYPE, 2018-2032 (USD MILLION)
  • TABLE 187. AFRICA URINARY TRACT INFECTION TESTING MARKET SIZE, BY INFECTION TYPE, 2018-2032 (USD MILLION)
  • TABLE 188. AFRICA URINARY TRACT INFECTION TESTING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 189. MIDDLE EAST URINARY TRACT INFECTION TESTING MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 190. MIDDLE EAST URINARY TRACT INFECTION TESTING MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 191. MIDDLE EAST URINARY TRACT INFECTION TESTING MARKET SIZE, BY AUTOMATED URINALYSIS, 2018-2032 (USD MILLION)
  • TABLE 192. MIDDLE EAST URINARY TRACT INFECTION TESTING MARKET SIZE, BY MOLECULAR TEST, 2018-2032 (USD MILLION)
  • TABLE 193. MIDDLE EAST URINARY TRACT INFECTION TESTING MARKET SIZE, BY RAPID TEST, 2018-2032 (USD MILLION)
  • TABLE 194. MIDDLE EAST URINARY TRACT INFECTION TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 195. MIDDLE EAST URINARY TRACT INFECTION TESTING MARKET SIZE, BY AUTOMATED SYSTEMS, 2018-2032 (USD MILLION)
  • TABLE 196. MIDDLE EAST URINARY TRACT INFECTION TESTING MARKET SIZE, BY IMMUNOASSAYS, 2018-2032 (USD MILLION)
  • TABLE 197. MIDDLE EAST URINARY TRACT INFECTION TESTING MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 198. MIDDLE EAST URINARY TRACT INFECTION TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 199. MIDDLE EAST URINARY TRACT INFECTION TESTING MARKET SIZE, BY PATHOGEN TYPE, 2018-2032 (USD MILLION)
  • TABLE 200. MIDDLE EAST URINARY TRACT INFECTION TESTING MARKET SIZE, BY INFECTION TYPE, 2018-2032 (USD MILLION)
  • TABLE 201. MIDDLE EAST URINARY TRACT INFECTION TESTING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 202. GLOBAL URINARY TRACT INFECTION TESTING MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 203. NATO URINARY TRACT INFECTION TESTING MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 204. NATO URINARY TRACT INFECTION TESTING MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 205. NATO URINARY TRACT INFECTION TESTING MARKET SIZE, BY AUTOMATED URINALYSIS, 2018-2032 (USD MILLION)
  • TABLE 206. NATO URINARY TRACT INFECTION TESTING MARKET SIZE, BY MOLECULAR TEST, 2018-2032 (USD MILLION)
  • TABLE 207. NATO URINARY TRACT INFECTION TESTING MARKET SIZE, BY RAPID TEST, 2018-2032 (USD MILLION)
  • TABLE 208. NATO URINARY TRACT INFECTION TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 209. NATO URINARY TRACT INFECTION TESTING MARKET SIZE, BY AUTOMATED SYSTEMS, 2018-2032 (USD MILLION)
  • TABLE 210. NATO URINARY TRACT INFECTION TESTING MARKET SIZE, BY IMMUNOASSAYS, 2018-2032 (USD MILLION)
  • TABLE 211. NATO URINARY TRACT INFECTION TESTING MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 212. NATO URINARY TRACT INFECTION TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 213. NATO URINARY TRACT INFECTION TESTING MARKET SIZE, BY PATHOGEN TYPE, 2018-2032 (USD MILLION)
  • TABLE 214. NATO URINARY TRACT INFECTION TESTING MARKET SIZE, BY INFECTION TYPE, 2018-2032 (USD MILLION)
  • TABLE 215. NATO URINARY TRACT INFECTION TESTING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 216. G7 URINARY TRACT INFECTION TESTING MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 217. G7 URINARY TRACT INFECTION TESTING MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 218. G7 URINARY TRACT INFECTION TESTING MARKET SIZE, BY AUTOMATED URINALYSIS, 2018-2032 (USD MILLION)
  • TABLE 219. G7 URINARY TRACT INFECTION TESTING MARKET SIZE, BY MOLECULAR TEST, 2018-2032 (USD MILLION)
  • TABLE 220. G7 URINARY TRACT INFECTION TESTING MARKET SIZE, BY RAPID TEST, 2018-2032 (USD MILLION)
  • TABLE 221. G7 URINARY TRACT INFECTION TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 222. G7 URINARY TRACT INFECTION TESTING MARKET SIZE, BY AUTOMATED SYSTEMS, 2018-2032 (USD MILLION)
  • TABLE 223. G7 URINARY TRACT INFECTION TESTING MARKET SIZE, BY IMMUNOASSAYS, 2018-2032 (USD MILLION)
  • TABLE 224. G7 URINARY TRACT INFECTION TESTING MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 225. G7 URINARY TRACT INFECTION TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 226. G7 URINARY TRACT INFECTION TESTING MARKET SIZE, BY PATHOGEN TYPE, 2018-2032 (USD MILLION)
  • TABLE 227. G7 URINARY TRACT INFECTION TESTING MARKET SIZE, BY INFECTION TYPE, 2018-2032 (USD MILLION)
  • TABLE 228. G7 URINARY TRACT INFECTION TESTING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 229. BRICS URINARY TRACT INFECTION TESTING MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 230. BRICS URINARY TRACT INFECTION TESTING MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 231. BRICS URINARY TRACT INFECTION TESTING MARKET SIZE, BY AUTOMATED URINALYSIS, 2018-2032 (USD MILLION)
  • TABLE 232. BRICS URINARY TRACT INFECTION TESTING MARKET SIZE, BY MOLECULAR TEST, 2018-2032 (USD MILLION)
  • TABLE 233. BRICS URINARY TRACT INFECTION TESTING MARKET SIZE, BY RAPID TEST, 2018-2032 (USD MILLION)
  • TABLE 234. BRICS URINARY TRACT INFECTION TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 235. BRICS URINARY TRACT INFECTION TESTING MARKET SIZE, BY AUTOMATED SYSTEMS, 2018-2032 (USD MILLION)
  • TABLE 236. BRICS URINARY TRACT INFECTION TESTING MARKET SIZE, BY IMMUNOASSAYS, 2018-2032 (USD MILLION)
  • TABLE 237. BRICS URINARY TRACT INFECTION TESTING MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 238. BRICS URINARY TRACT INFECTION TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 239. BRICS URINARY TRACT INFECTION TESTING MARKET SIZE, BY PATHOGEN TYPE, 2018-2032 (USD MILLION)
  • TABLE 240. BRICS URINARY TRACT INFECTION TESTING MARKET SIZE, BY INFECTION TYPE, 2018-2032 (USD MILLION)
  • TABLE 241. BRICS URINARY TRACT INFECTION TESTING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 242. EUROPEAN UNION URINARY TRACT INFECTION TESTING MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 243. EUROPEAN UNION URINARY TRACT INFECTION TESTING MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 244. EUROPEAN UNION URINARY TRACT INFECTION TESTING MARKET SIZE, BY AUTOMATED URINALYSIS, 2018-2032 (USD MILLION)
  • TABLE 245. EUROPEAN UNION URINARY TRACT INFECTION TESTING MARKET SIZE, BY MOLECULAR TEST, 2018-2032 (USD MILLION)
  • TABLE 246. EUROPEAN UNION URINARY TRACT INFECTION TESTING MARKET SIZE, BY RAPID TEST, 2018-2032 (USD MILLION)
  • TABLE 247. EUROPEAN UNION URINARY TRACT INFECTION TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 248. EUROPEAN UNION URINARY TRACT INFECTION TESTING MARKET SIZE, BY AUTOMATED SYSTEMS, 2018-2032 (USD MILLION)
  • TABLE 249. EUROPEAN UNION URINARY TRACT INFECTION TESTING MARKET SIZE, BY IMMUNOASSAYS, 2018-2032 (USD MILLION)
  • TABLE 250. EUROPEAN UNION URINARY TRACT INFECTION TESTING MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 251. EUROPEAN UNION URINARY TRACT INFECTION TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 252. EUROPEAN UNION URINARY TRACT INFECTION TESTING MARKET SIZE, BY PATHOGEN TYPE, 2018-2032 (USD MILLION)
  • TABLE 253. EUROPEAN UNION URINARY TRACT INFECTION TESTING MARKET SIZE, BY INFECTION TYPE, 2018-2032 (USD MILLION)
  • TABLE 254. EUROPEAN UNION URINARY TRACT INFECTION TESTING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 255. ASEAN URINARY TRACT INFECTION TESTING MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 256. ASEAN URINARY TRACT INFECTION TESTING MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 257. ASEAN URINARY TRACT INFECTION TESTING MARKET SIZE, BY AUTOMATED URINALYSIS, 2018-2032 (USD MILLION)
  • TABLE 258. ASEAN URINARY TRACT INFECTION TESTING MARKET SIZE, BY MOLECULAR TEST, 2018-2032 (USD MILLION)
  • TABLE 259. ASEAN URINARY TRACT INFECTION TESTING MARKET SIZE, BY RAPID TEST, 2018-2032 (USD MILLION)
  • TABLE 260. ASEAN URINARY TRACT INFECTION TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 261. ASEAN URINARY TRACT INFECTION TESTING MARKET SIZE, BY AUTOMATED SYSTEMS, 2018-2032 (USD MILLION)
  • TABLE 262. ASEAN URINARY TRACT INFECTION TESTING MARKET SIZE, BY IMMUNOASSAYS, 2018-2032 (USD MILLION)
  • TABLE 263. ASEAN URINARY TRACT INFECTION TESTING MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 264. ASEAN URINARY TRACT INFECTION TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 265. ASEAN URINARY TRACT INFECTION TESTING MARKET SIZE, BY PATHOGEN TYPE, 2018-2032 (USD MILLION)
  • TABLE 266. ASEAN URINARY TRACT INFECTION TESTING MARKET SIZE, BY INFECTION TYPE, 2018-2032 (USD MILLION)
  • TABLE 267. ASEAN URINARY TRACT INFECTION TESTING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 268. GCC URINARY TRACT INFECTION TESTING MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 269. GCC URINARY TRACT INFECTION TESTING MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 270. GCC URINARY TRACT INFECTION TESTING MARKET SIZE, BY AUTOMATED URINALYSIS, 2018-2032 (USD MILLION)
  • TABLE 271. GCC URINARY TRACT INFECTION TESTING MARKET SIZE, BY MOLECULAR TEST, 2018-2032 (USD MILLION)
  • TABLE 272. GCC URINARY TRACT INFECTION TESTING MARKET SIZE, BY RAPID TEST, 2018-2032 (USD MILLION)
  • TABLE 273. GCC URINARY TRACT INFECTION TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 274. GCC URINARY TRACT INFECTION TESTING MARKET SIZE, BY AUTOMATED SYSTEMS, 2018-2032 (USD MILLION)
  • TABLE 275. GCC URINARY TRACT INFECTION TESTING MARKET SIZE, BY IMMUNOASSAYS, 2018-2032 (USD MILLION)
  • TABLE 276. GCC URINARY TRACT INFECTION TESTING MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 277. GCC URINARY TRACT INFECTION TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 278. GCC URINARY TRACT INFECTION TESTING MARKET SIZE, BY PATHOGEN TYPE, 2018-2032 (USD MILLION)
  • TABLE 279. GCC URINARY TRACT INFECTION TESTING MARKET SIZE, BY INFECTION TYPE, 2018-2032 (USD MILLION)
  • TABLE 280. GCC URINARY TRACT INFECTION TESTING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 281. GLOBAL URINARY TRACT INFECTION TESTING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 282. CHINA URINARY TRACT INFECTION TESTING MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 283. CHINA URINARY TRACT INFECTION TESTING MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 284. CHINA URINARY TRACT INFECTION TESTING MARKET SIZE, BY AUTOMATED URINALYSIS, 2018-2032 (USD MILLION)
  • TABLE 285. CHINA URINARY TRACT INFECTION TESTING MARKET SIZE, BY MOLECULAR TEST, 2018-2032 (USD MILLION)
  • TABLE 286. CHINA URINARY TRACT INFECTION TESTING MARKET SIZE, BY RAPID TEST, 2018-2032 (USD MILLION)
  • TABLE 287. CHINA URINARY TRACT INFECTION TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 288. CHINA URINARY TRACT INFECTION TESTING MARKET SIZE, BY AUTOMATED SYSTEMS, 2018-2032 (USD MILLION)
  • TABLE 289. CHINA URINARY TRACT INFECTION TESTING MARKET SIZE, BY IMMUNOASSAYS, 2018-2032 (USD MILLION)
  • TABLE 290. CHINA URINARY TRACT INFECTION TESTING MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 291. CHINA URINARY TRACT INFECTION TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 292. CHINA URINARY TRACT INFECTION TESTING MARKET SIZE, BY PATHOGEN TYPE, 2018-2032 (USD MILLION)
  • TABLE 293. CHINA URINARY TRACT INFECTION TESTING MARKET SIZE, BY INFECTION TYPE, 2018-2032 (USD MILLION)
  • TABLE 294. CHINA URINARY TRACT INFECTION TESTING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 295. UNITED STATES URINARY TRACT INFECTION TESTING MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 296. UNITED STATES URINARY TRACT INFECTION TESTING MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 297. UNITED STATES URINARY TRACT INFECTION TESTING MARKET SIZE, BY AUTOMATED URINALYSIS, 2018-2032 (USD MILLION)
  • TABLE 298. UNITED STATES URINARY TRACT INFECTION TESTING MARKET SIZE, BY MOLECULAR TEST, 2018-2032 (USD MILLION)
  • TABLE 299. UNITED STATES URINARY TRACT INFECTION TESTING MARKET SIZE, BY RAPID TEST, 2018-2032 (USD MILLION)
  • TABLE 300. UNITED STATES URINARY TRACT INFECTION TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 301. UNITED STATES URINARY TRACT INFECTION TESTING MARKET SIZE, BY AUTOMATED SYSTEMS, 2018-2032 (USD MILLION)
  • TABLE 302. UNITED STATES URINARY TRACT INFECTION TESTING MARKET SIZE, BY IMMUNOASSAYS, 2018-2032 (USD MILLION)
  • TABLE 303. UNITED STATES URINARY TRACT INFECTION TESTING MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 304. UNITED STATES URINARY TRACT INFECTION TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 305. UNITED STATES URINARY TRACT INFECTION TESTING MARKET SIZE, BY PATHOGEN TYPE, 2018-2032 (USD MILLION)
  • TABLE 306. UNITED STATES URINARY TRACT INFECTION TESTING MARKET SIZE, BY INFECTION TYPE, 2018-2032 (USD MILLION)
  • TABLE 307. UNITED STATES URINARY TRACT INFECTION TESTING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 308. JAPAN URINARY TRACT INFECTION TESTING MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 309. JAPAN URINARY TRACT INFECTION TESTING MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 310. JAPAN URINARY TRACT INFECTION TESTING MARKET SIZE, BY AUTOMATED URINALYSIS, 2018-2032 (USD MILLION)
  • TABLE 311. JAPAN URINARY TRACT INFECTION TESTING MARKET SIZE, BY MOLECULAR TEST, 2018-2032 (USD MILLION)
  • TABLE 312. JAPAN URINARY TRACT INFECTION TESTING MARKET SIZE, BY RAPID TEST, 2018-2032 (USD MILLION)
  • TABLE 313. JAPAN URINARY TRACT INFECTION TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 314. JAPAN URINARY TRACT INFECTION TESTING MARKET SIZE, BY AUTOMATED SYSTEMS, 2018-2032 (USD MILLION)
  • TABLE 315. JAPAN URINARY TRACT INFECTION TESTING MARKET SIZE, BY IMMUNOASSAYS, 2018-2032 (USD MILLION)
  • TABLE 316. JAPAN URINARY TRACT INFECTION TESTING MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 317. JAPAN URINARY TRACT INFECTION TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 318. JAPAN URINARY TRACT INFECTION TESTING MARKET SIZE, BY PATHOGEN TYPE, 2018-2032 (USD MILLION)
  • TABLE 319. JAPAN URINARY TRACT INFECTION TESTING MARKET SIZE, BY INFECTION TYPE, 2018-2032 (USD MILLION)
  • TABLE 320. JAPAN URINARY TRACT INFECTION TESTING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 321. INDIA URINARY TRACT INFECTION TESTING MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 322. INDIA URINARY TRACT INFECTION TESTING MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 323. INDIA URINARY TRACT INFECTION TESTING MARKET SIZE, BY AUTOMATED URINALYSIS, 2018-2032 (USD MILLION)
  • TABLE 324. INDIA URINARY TRACT INFECTION TESTING MARKET SIZE, BY MOLECULAR TEST, 2018-2032 (USD MILLION)
  • TABLE 325. INDIA URINARY TRACT INFECTION TESTING MARKET SIZE, BY RAPID TEST, 2018-2032 (USD MILLION)
  • TABLE 326. INDIA URINARY TRACT INFECTION TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 327. INDIA URINARY TRACT INFECTION TESTING MARKET SIZE, BY AUTOMATED SYSTEMS, 2018-2032 (USD MILLION)
  • TABLE 328. INDIA URINARY TRACT INFECTION TESTING MARKET SIZE, BY IMMUNOASSAYS, 2018-2032 (USD MILLION)
  • TABLE 329. INDIA URINARY TRACT INFECTION TESTING MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 330. INDIA URINARY TRACT INFECTION TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 331. INDIA URINARY TRACT INFECTION TESTING MARKET SIZE, BY PATHOGEN TYPE, 2018-2032 (USD MILLION)
  • TABLE 332. INDIA URINARY TRACT INFECTION TESTING MARKET SIZE, BY INFECTION TYPE, 2018-2032 (USD MILLION)
  • TABLE 333. INDIA URINARY TRACT INFECTION TESTING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 334. GERMANY URINARY TRACT INFECTION TESTING MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 335. GERMANY URINARY TRACT INFECTION TESTING MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 336. GERMANY URINARY TRACT INFECTION TESTING MARKET SIZE, BY AUTOMATED URINALYSIS, 2018-2032 (USD MILLION)

TABLE 337.